PMID- 10051726
OWN - NLM
STAT- MEDLINE
DCOM- 19990427
LR  - 20190831
IS  - 0954-7894 (Print)
IS  - 0954-7894 (Linking)
VI  - 29
IP  - 2
DP  - 1999 Feb
TI  - The late asthmatic response is associated with baseline allergen-specific 
      proliferative responsiveness of peripheral T lymphocytes in vitro and serum 
      interleukin-5.
PG  - 217-27
AB  - BACKGROUND: Increasing insights into the mechanism underlying the 
      allergen-induced late asthmatic response (LAR) have been gained with implication 
      of activated eosinophils and CD4+ T lymphocytes. However, the patient 
      characteristics that indicate the individual capacity to develop a LAR are not 
      well-defined. METHODS: In 22 subjects with mild to moderate house dust 
      mite-allergic asthma, we investigated the relationship between the LAR and two 
      other models of late-phase allergic inflammation, i.e. the allergen-specific 
      proliferative response of peripheral blood T lymphocytes in vitro and the late 
      cutaneous response. Non-specific bronchial responsiveness (PC20histamine), lung 
      function (FEV1), peripheral blood eosinophil count, early phase allergic skin 
      sensitivity, and levels of total and specific immunoglobulin E (IgE) were 
      determined prior to bronchial allergen challenge. Serum levels of interleukin-5 
      (IL-5) were measured before and at several time points after allergen inhalation. 
      RESULTS: A significant correlation was found between the magnitude of the LAR and 
      the allergen-specific proliferative response of peripheral T lymphocytes (r = 
      0.44, P = 0.04) but not the late cutaneous response. Stepwise-multiple linear 
      regression of the magnitude of the LAR on the parameters analysed at baseline, 
      resulted in a model combining PC20 histamine, early phase allergic skin 
      sensitivity, and the allergen-specific proliferative response of peripheral T 
      lymphocytes (R2 = 0.84, P<0.001). No contribution of the late cutaneous response 
      to the prediction of the LAR was found. Serum levels of IL-5 increased 
      significantly at 6 h (P = 0.01) and 24 h (P = 0.003) after bronchial allergen 
      challenge and correlated with the allergen-specific proliferative response of 
      peripheral T lymphocytes in vitro (rho = 0.48, P = 0.02). CONCLUSIONS: The 
      findings in this study point to a role of TH2-lymphocyte responses in the 
      development of the allergen-induced LAR. In allergic asthmatic patients, 
      allergen-specific responsiveness of peripheral T-lymphocytes in vitro may serve 
      as a model to determine the individual capacity to develop a LAR after allergen 
      inhalation.
FAU - van der Veen, M J
AU  - van der Veen MJ
AD  - Department of Pulmonology, Academic Medical Center, University of Amsterdam, The 
      Netherlands.
FAU - Van Neerven, R J
AU  - Van Neerven RJ
FAU - De Jong, E C
AU  - De Jong EC
FAU - Aalberse, R C
AU  - Aalberse RC
FAU - Jansen, H M
AU  - Jansen HM
FAU - van der Zee, J S
AU  - van der Zee JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Glycoproteins)
RN  - 0 (Interleukin-5)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 820484N8I3 (Histamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allergens/*immunology
MH  - Animals
MH  - Antigens, Dermatophagoides
MH  - Asthma/*immunology
MH  - Bronchial Provocation Tests
MH  - Female
MH  - Glycoproteins/*immunology
MH  - Histamine
MH  - Humans
MH  - Immunoglobulin E/analysis
MH  - Interleukin-5/blood
MH  - *Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - Mites/*immunology
MH  - Skin/immunology
MH  - Skin Tests
MH  - T-Lymphocytes/*immunology
EDAT- 1999/03/03 00:00
MHDA- 1999/03/03 00:01
CRDT- 1999/03/03 00:00
PHST- 1999/03/03 00:00 [pubmed]
PHST- 1999/03/03 00:01 [medline]
PHST- 1999/03/03 00:00 [entrez]
AID - 10.1046/j.1365-2222.1999.00466.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 1999 Feb;29(2):217-27. doi: 10.1046/j.1365-2222.1999.00466.x.